Androgen-receptor coregulators mediate the suppressive effect of androgen signals on vitamin D receptor activity

被引:0
作者
Huei-Ju Ting
Bo-Ying Bao
Cheng-Lung Hsu
Yi-Fen Lee
机构
[1] University of Rochester,Department of Urology
[2] University of Rochester,Department of Chemical Engineering
来源
Endocrine | 2005年 / 26卷
关键词
1α,25-Dihydroxyvitamin D; vitamin D; receptor; androgen receptor; coregulators;
D O I
暂无
中图分类号
学科分类号
摘要
Overexpression of androgen receptors (AR) in PC-3 cell, and treatment of 5α-dihydrotestosterone in LNCaP cells lead to the suppression of VDR transactivation. Competition for shared coregulators between AR and VDR is one possible mechanism to explain the suppressive effect of androgen-AR signals on VDR activity. Among the AR coregulators we tested, ARA54, ARA70, supervillin, and gelsolin were found to enhance VDR transactivation. Further characterization of the interaction between ARA54 or ARA70 and VDR demonstrated a direct interaction between VDR and ARA70, but no association between ARA54 and VDR. The LXXLL motif of ARA70 is essential for interaction with VDR and partially responsible for its function as a coactivator of VDR. The suppression of VDR transactivation by AR signal was restored by overexpression of ARA70, but not ARA54. Together, ARA70 and ARA54 modulate VDR transactivation, and the competition for ARA70 mediates the suppressive effect of androgen-AR on VDR transactivation.
引用
收藏
页码:1 / 9
页数:8
相关论文
共 80 条
[1]  
Hansen C. M.(2001)undefined Front Biosci. 6 D820-D848
[2]  
Binderup L.(2002)undefined Cancer Metastasis Rev. 21 147-158
[3]  
Hamberg K. J.(1997)undefined Mol. Cell Endocrinol. 126 83-90
[4]  
Carlberg C.(2000)undefined Endocrinology 141 2548-2556
[5]  
Johnson C. S.(2001)undefined Nat. Rev. Cancer 1 34-45
[6]  
Hershberger P. A.(2001)undefined Cancer Res. 61 4315-4319
[7]  
Trump D. L.(2003)undefined Cancer Res. 63 4888-4894
[8]  
Zhuang S. H.(2002)undefined Cancer Res. 62 6039-6044
[9]  
Schwartz G. G.(1999)undefined J. Biol. Chem. 274 8570-8576
[10]  
Cameron D.(2002)undefined Endocr. Rev. 23 175-200